Clinical features in osteosarcoma and prognostic implications;Características clínicas do osteossarcoma na infância e sua influência no prognóstico

Jornal de Pediatria

Volumn 80, Issue 1, 2004, Pages 65-70

  Rech, Ângela ^a   Castro Jr , Cláudio G ^a,b,c   Mattei, Jane ^c   Gregianin, Lauro ^a,c   Di Leone, Luciane ^a,c   David, Alexandre ^d   Rivero, Luis F ^a,c   Tarrago, Ricardo ^e   Abreu, Armando ^f   Brunetto, Algemir L ^a,c,g,h  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b Prog de Pos graduacao em Cie Med

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d Grp Tum Aparelho Locomotor S Casa

^e Grp Tum Aparelho Locomotor S Casa ^*  (Brazil)

^f HOSPITAL MÃE DE DEUS   (Brazil)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

^h UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

Author keywords

Children; Metastatic; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IFOSFAMIDE; LACTATE DEHYDROGENASE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; BRAZIL; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; FEMALE; FIBULA; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; PROGNOSIS; TIBIA; TUMOR LOCALIZATION; TUMOR NECROSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; L-LACTATE DEHYDROGENASE; MALE; OSTEOSARCOMA; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11144356867     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/1136     Document Type: Article

References (20)

1. Link M, Eilber F. Osteosarcoma. In: Pizzo P, Poplack D. Principles and Practice of Pediatric Oncology. 4th ed. Philadelphia: Lippincott - Raven Publishers; 2002. p. 1051-1089.
2. Gurney JG, Swensen AR, Bulterys M. Bone Tumor. In: Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975. 1999;994649:99-109.
3. Petrilli AS, Gentil FC, Epelman S, Lopes LF, Bianchi A, Lopes A, et al. Increased survival, limb preservation, and prognostic factors for osteosarcoma. Cancer. 1991;68:733-7.
4. Schajowicz F, Ackerman LV, Sisson HA. Histological typing of bone tumors. International Histological Classification of Tumors. N.6. Geneva; 1992.
5. Meyers P, Gorlick R. Osteossarcoma. In: Link M. Clínicas Pediátricas da América do Norte. Belo Horizonte: Interlivros; 1997. p. 981-999.
6. Bieling P, Rehan N, Winkler P. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14: 848-58.
7. Goorin A, Baker A, Giese P. No evidence for improved event free survival with presurgical chemotherapy for non-metastatic extremity osteogenic sarcoma: preliminary results of randomized Pediatric Oncology Group trial 8651 [abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:A-1420. n. 444.
8. Davi A, Rios AR, Tarrago R, Rotta NW, Brunetto AL, Abreu A. Auto-enxerto tumoral irradiado nas reconstruções dos tumores ósseos. Revista Brasileira de Ortopedia. 2000;35:325-32.
9. Meyer WH, Pratt CB, Poquette CA, Rao BN, Parham DM, Marina NM, et al. Carboplatin/Ifosfamide Window Therapy for Osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 Trial. J Clin Oncol. 2001;19;171-82.
10. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776-90.
11. Bacci C, Ferrari S, Longhi A, Forni C, Zavatta M, Versari M, et al. High-grade Osteosarcoma of extremity; differences between localized and metastatic tumors at presentation. J Pediatr Hematol Oncol. 2002;24:27-30.
12. Pochanugool L, Subhadharaphandou T, Dhanachai M, Hathirat P, Sangthawan D, Pirabul R, et al. Prognostic factors among 130 patients with osteosarcoma. Clin Orthop. 1997;345:206-14.
13. Feugeas O, Guriec N, Babin-Boilletot A. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with Osteosarcoma. J Clin Oncol. 1996;14:467-72.
14. Gorlick R, Huvos AG, Heller G. Expression of HERZ/erb-2 correlates with survival in Osteosarcoma. J Clin Oncol. 1999;17:2781-8.
15. Onda M, Matsuda S, Higalci S. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996;77(1):71-8.
16. Link MP, Goorin AM, Horowitz M. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institucional Osteosarcoma Study. Clin Orthop. 1991;8-14.
17. Reddick WE, Wang S, Xiong X. Dynamic magnetic resonance imaging of regional contrast access as an additional prognostic factor in pediatric osteosarcoma. Cancer. 2001;91:2230-7.
18. Davis AM, Bell RS, Goodwin PJ. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994;12;423-31.
19. Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Huvos AG, et al. Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy; a report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
20. Weeden S, Grimer RJ, Cannon SR. European Osteosarcoma Interproup: The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer. 2001;37:39-46.